As of Feb 23
| +0.15 / +3.04%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +37.80% increase from the last price of 5.08.
The current consensus among 8 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.